Routine RTA compliance certificate for Q2 FY27 dematerialisation

Compliance View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹750.00

prior close

₹750.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.8%-0.8% vs market

Pharmaceuticals peers, median of 167sector-0.1%+0.2% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.0

10m

+1.5

15m

+2.9

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.8-0.8-0.1+0.2

Next day

+2.9+1.0+1.9-0.1+3.1

+3.5+1.7+1.7-0.3+3.8

-0.5+0.1-0.6-1.0+0.4

-2.5+0.8-3.3-0.7-1.8

-5.7-0.9-4.8-2.2-3.5

-10.0-4.5-5.5-4.4-5.6

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals has submitted a certificate from its Registrar and Share Transfer Agent MUFG Intime India, confirming compliance with SEBI Regulation 74(5) for the quarter ended 30 September 2026. The certificate confirms that securities received from depository participants for dematerialisation were processed and the share certificates were mutilated and cancelled, with the depository recorded as the registered owner within the prescribed timelines.

Likely market impact

Routine procedural filing with no impact on business, financials, or share price.